The recent decision by the Union Ministry of Health and Family Welfare to ban 16 Fixed Dose Combinations (FDCs) has sparked concern among patients and healthcare professionals alike. These FDCs, which include various combinations of antibiotics, antispasmodics, cosmetics, and diabetes/pain-related medications, have been deemed to offer no real therapeutic value by the Drugs Technical Advisory Board (DTAB).
This move is a significant step towards ensuring that only FDCs with proven efficacy, safety, and meaningful patient benefit remain available for clinical use. It highlights the importance of evidence-based prescribing and the need for scientifically validated formulations.
Dr. Aniket Mule, a consultant in internal medicine, emphasizes the principle that each component of a drug combination should have a clear scientific purpose and proven benefit. He warns that unnecessary combinations can lead to more side effects, drug interactions, higher costs, and confusion about the cause of negative reactions.
Dr. Shweta Nakhawa, a dermatologist, notes that several banned FDCs are in the skincare and dermatology category, raising concerns about the lack of scientific evidence supporting their combined benefits. She advises patients to consult dermatologists for suitable alternatives instead of self-medicating.
Dr. Rajiv Kovil, a diabetes and obesity specialist, appreciates the government's emphasis on therapeutic justification and scientific validation. He highlights the case of Gliclazide plus Chromium Picolinate, where the combination lacks robust randomised controlled trial evidence and is not endorsed by international guidelines.
Despite the concerns, experts urge patients not to panic. Dr. Mule advises those taking affected medications to consult their doctors about suitable alternatives, ensuring that treatments are backed by solid clinical evidence and established safety data.
This regulatory action serves as a reminder of the importance of evidence-based medicine and the need for healthcare professionals to prioritize scientifically validated formulations. It also underscores the potential risks of unnecessary drug combinations and the need for patients to be informed and proactive in their healthcare decisions.
